Table 2.
Summary of recommendations in the ESCMID, IDSA and SEIMC guidelines for the treatment of infections due to carbapenemase producing Enterobacterales. Dosages of the different antimicrobials are those included in the Summary of Product Characteristics (SmPC).
| Society Year of publication |
Carbapenemase type | ||
|---|---|---|---|
| KPC | OXA-48 | MBL | |
| ESCMID 2021 |
Ceftazidime–avibactam* Meropenem–vaborbactam |
Ceftazidime-avibactam | Ceftazidime–avibactam + aztreonam Cefiderocol |
| Non-severe infection: Aminoglycosides (UTI) or tigecycline (not in bacteraemia /pneumonia) | |||
| IDSA 2022 |
Ceftazidime–avibactam Meropenem–vaborbactam Imipenem–relebactam |
Ceftazidime-avibactam | Ceftazidime–avibactam + aztreonam Cefiderocol |
| UTI →Aminoglycosides, cefiderocol, meropenem Abdominal →Tigecycline, eravacycline | |||
| SEIMC 2022 |
Ceftazidime–avibactam Meropenem–vaborbactam |
Ceftazidime-avibactam | Ceftazidime–avibactam + aztreonam Cefiderocol |
| Alternative →Combined therapy (meropenem, colistin, tigecycline, aminoglycosides…) | |||
UTI: urinary tract infection.